Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Bioequivalence: Overview01:16

Bioequivalence: Overview

1.2K
Pharmaceutical equivalents, by definition, are drug products with the same active ingredient in the same quantities, encapsulated in identical dosage forms, and intended for the same administration routes. These pharmaceutical equivalents are deemed bioequivalent if the bioavailability of the active entity in the drug preparations is similar. Moreover, pharmaceutical equivalents demonstrating bioequivalence are also regarded as therapeutically equivalent. This means that when used as directed,...
1.2K
Biopharmaceutics and Pharmacokinetics: Overview01:28

Biopharmaceutics and Pharmacokinetics: Overview

2.3K
Understanding drugs, drug products, and their performance in pharmaceutical science is pivotal. Drugs, whether simple molecules or complex compounds, are designed to interact with the body's biological systems to diagnose, treat, or prevent diseases. Drug products include various delivery systems such as tablets, capsules, injections, and inhalers. The performance of these drug products is gauged by their ability to deliver the active ingredient to the desired site of action at the...
2.3K
Pharmacovigilance01:19

Pharmacovigilance

951
Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
951
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches01:23

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches

157
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
157
Pharmacokinetic Models: Overview01:20

Pharmacokinetic Models: Overview

924
Pharmacokinetic models utilize mathematical analysis to achieve a detailed quantitative understanding of a drug's life cycle within the body. They are instrumental in simulating a drug's pharmacokinetic parameters, predicting drug concentrations over time, optimizing dosage regimens, linking concentrations with pharmacologic activity, and estimating potential toxicity.
There are three primary types of models: empirical, compartment, and physiological. Empirical models, with minimal...
924
Analysis of Population Pharmacokinetic Data01:12

Analysis of Population Pharmacokinetic Data

345
Analysis of population pharmacokinetic data involves studying the behavior of drugs within diverse populations to understand their pharmacokinetic parameters. Traditional pharmacokinetic methods typically involve collecting samples from a few individuals and estimating these parameters. While these methods are commonly used, they have limitations in capturing the variability in drug response among individuals or heterogeneous populations. Population pharmacokinetics is employed to address these...
345

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Value frameworks for digital health technologies: a comparative analysis.

Journal of medical economics·2026
Same author

Complete renal duplication with lower pole obstructive ectopic ureter - An exception of the Weigert-Meyer rule.

Urology case reports·2025
Same author

Five-year molecular response and overall survival with first- and second-generation tyrosine kinase inhibitors in patients with chronic myeloid leukemia in the chronic phase: a prospective, observational study - SIMPLICITY.

Leukemia & lymphoma·2025
Same author

Editorial Comment.

The Journal of urology·2024
Same author

Real-world impact of luspatercept on red blood cell transfusions among patients with myelodysplastic syndromes: A United States healthcare claims database study.

Leukemia research·2024
Same author

Immunogenicity of adalimumab reference product and adalimumab-adbm in patients with rheumatoid arthritis, Crohn's disease and chronic plaque psoriasis: a pooled analysis of the VOLTAIRE trials.

BMJ open·2024

Related Experiment Video

Updated: Aug 19, 2025

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis
07:25

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis

Published on: May 4, 2017

17.8K

Pharmacist biosimilar survey reveals knowledge gaps.

James G Stevenson, Dorothy McCabe, Melissa McGrath

    Journal of the American Pharmacists Association : Japha
    |November 27, 2022
    PubMed
    Summary
    This summary is machine-generated.

    Pharmacists show high awareness of biosimilar efficacy and safety but lack understanding of interchangeability. Further education is needed to improve pharmacist confidence in discussing biosimilars with patients.

    More Related Videos

    Evidence-based Knowledge Synthesis and Hypothesis Validation: Navigating Biomedical Knowledge Bases via Explainable AI and Agentic Systems
    05:47

    Evidence-based Knowledge Synthesis and Hypothesis Validation: Navigating Biomedical Knowledge Bases via Explainable AI and Agentic Systems

    Published on: June 13, 2025

    502
    Laboratory Scale Production and Purification of a Therapeutic Antibody
    09:54

    Laboratory Scale Production and Purification of a Therapeutic Antibody

    Published on: January 24, 2017

    17.5K

    Related Experiment Videos

    Last Updated: Aug 19, 2025

    In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis
    07:25

    In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis

    Published on: May 4, 2017

    17.8K
    Evidence-based Knowledge Synthesis and Hypothesis Validation: Navigating Biomedical Knowledge Bases via Explainable AI and Agentic Systems
    05:47

    Evidence-based Knowledge Synthesis and Hypothesis Validation: Navigating Biomedical Knowledge Bases via Explainable AI and Agentic Systems

    Published on: June 13, 2025

    502
    Laboratory Scale Production and Purification of a Therapeutic Antibody
    09:54

    Laboratory Scale Production and Purification of a Therapeutic Antibody

    Published on: January 24, 2017

    17.5K

    Area of Science:

    • Pharmacy Practice
    • Pharmacoeconomics
    • Biologics

    Background:

    • Biosimilars are crucial for pharmacy practice, enhancing patient access to biologics and reducing healthcare expenses.
    • Understanding biosimilars is vital for pharmacists to effectively manage biologic therapies.

    Purpose of the Study:

    • To evaluate pharmacists' comprehension of biosimilars, including their interchangeability.
    • To identify knowledge gaps and comfort levels among pharmacists regarding biosimilar products.

    Main Methods:

    • A web-based survey was conducted in March 2021 among pharmacists and certified pharmacy technicians (CPTs).
    • The survey included true/false and Likert-type questions, gathering responses from 507 eligible participants across various pharmacy settings.

    Main Results:

    • While 87-91% recognized biosimilar efficacy and safety, only 20% understood pharmacist substitution of interchangeable biosimilars without prescriber approval.
    • Over 50% found dispensing interchangeable biosimilars appropriate if state law permitted, but awareness of interchangeability designation was low (11%).
    • Slightly over half felt moderately to very comfortable answering patient questions about biosimilars.

    Conclusions:

    • Significant gaps persist in pharmacists' understanding of biosimilar interchangeability.
    • Further educational initiatives are necessary to enhance pharmacists' knowledge and comfort with biosimilar products and their appropriate use.